Ask AI
ProCE Banner Events

Share

Integrating CAR T-Cell Therapy into Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes

Join us for breakfast (virtually) during ASCO for 1-hour CME-certified webinar on CAR T cell therapy in patients with lymphoma. This interactive, expert round-table event will feature expert’s perspectives on the application of CAR T cell therapy in DLBCL, FL, MCL, and CLL/SLL, including recent clinical data, FDA-approved indications, and strategies for managing CAR T therapy-related toxicities. Bring your questions for the question-and-answer session with the expert faculty.

Sign up now!

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas.

Time and location

Saturday, June 03, 2023

6:30 AM - 7:30 AM Central Time (CT)

Virtual

Agenda

Welcome, and Polling Questions

Introduction

  • Overview of CAR T-cell therapy
  • Clinical data for CAR T-cell therapies in hematologic malignancies

Current Treatment Algorithms

  • Current indications for CAR T-cell therapies

Oncologist Management of CAR T-Related toxicities

  • Adverse event profiles and management guides and resources

Summary, Final Thoughts, Audience Q&A

CME/CE Info

Program Overview
Join us for breakfast (virtually) during ASCO for 1-hour CME-certified webinar on CAR T cell therapy in patients with lymphoma. This interactive, expert round-table event will feature expert’s perspectives on the application of CAR T cell therapy in DLBCL, FL, MCL, and CLL/SLL, including recent clinical data, FDA-approved indications, and strategies for managing CAR T therapy-related toxicities. Bring your questions for the question-and-answer session with the expert faculty. 

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinal practice. 

Target Audience
This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recall the scientific rationale, key evidence, and expanding role of current and emerging CAR T-cell therapies in CLL/SLL, DLBCL, FL, and MCL
  • Plan individualized therapeutic strategies to optimize integration of CAR T-cell therapies for patients with hematologic malignancies including patient selection, referral to specialized CAR T-cell treatment centers, patient care coordination, and pre/post treatment support
  • Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies in patients with hematologic malignancies
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies for appropriate and inclusive patient enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinal practice. 

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.